ImmunityBio Shares Climbed as Aetna Expanded Cancer Care
The company reported share growth amid a strategic expansion of bundled cancer-care authorizations by Aetna.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Is now a good time to invest in individual biotechnology stocks?
ImmunityBio shares reached $9.75 on October 7, 2026, marking a 0.6% daily gain as the firm linked with Aetna for cancer care. The initiative follows Aetna's September expansion of bundled treatment approvals for Medicaid members.
Why it matters
Aetna is seeking to streamline the prior authorization process for cancer patients by using the Eviti platform to evaluate treatment plans against clinical evidence. This move reduces the administrative burden on providers by processing broader care plans rather than individual requests.
ImmunityBio's Anktiva is currently authorized for use in 34 countries after receiving FDA approval in April 2024. The firm's shares saw a 392% increase year-to-date, despite a weekly drop of 5%.
The players
ImmunityBio
This biotechnology company focuses on developing therapies for cancer and infectious diseases.
Aetna
Aetna is a major American health insurance provider that manages coverage for millions of members.
Patrick Soon-Shiong
He is the founder of ImmunityBio and a prominent physician, researcher, and entrepreneur.
The details
Aetna utilizes the Eviti platform to verify oncology treatment plans against insurance policies and clinical standards. This collaboration aims to bundle treatment approvals, allowing providers to submit comprehensive plans through a single portal.
Timeline
April 2024: Anktiva received initial FDA approval for bladder cancer treatment.
September 1, 2026: Aetna expanded bundled cancer-care approvals for Medicaid members.
October 7, 2026: ImmunityBio shares traded at $9.75.
January 6, 2027: The FDA is expected to reach a decision on an Anktiva label expansion.
First half of 2027: Aetna plans to expand bundled approvals to Medicare and commercial plans.
Deeper Dive
This story tracks the commercial and procedural growth following the FDA's Anktiva bladder cancer approval. It represents a pivot toward scaling access through integrated insurance platforms.
Eligible patients may experience faster treatment start times as providers use the Eviti platform to streamline prior authorizations. This initiative currently impacts Medicaid members, with broader expansions to Medicare and commercial plans expected in early 2027.
The takeaway
Streamlined authorization processes represent a growing trend in oncology where insurers and biotechs align to reduce clinical administrative delays. Patients and providers should monitor their specific insurance plan updates as these bundled programs expand through 2027.
What happens next
The FDA is scheduled to reach a decision on expanding the label for Anktiva specifically for papillary-only disease on January 6, 2027.
Further reading
Learn more about the latest developments in Cancer research and treatment standards.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Is now a good time to invest in individual biotechnology stocks?
